How to Get Trulicity in New Hampshire

Who Can Prescribe Trulicity in New Hampshire

Any clinician holding prescriptive authority in the state of New Hampshire may write a Trulicity prescription. That includes physicians (MD and DO), nurse practitioners, and physician assistants. New Hampshire grants NPs full practice authority, meaning NPs can prescribe GLP-1 receptor agonists independently without a collaborating physician agreement.

For patients without an established provider, telehealth platforms staffed by New Hampshire-licensed clinicians offer a direct path to evaluation and prescribing. NH RSA 329:1-d permits the establishment of a provider-patient relationship via synchronous audio-video visit, so no in-person appointment is required for the initial consultation. The prescriber must verify the patient's New Hampshire address and hold an active license through the New Hampshire Board of Medicine or Board of Nursing.

Primary care physicians remain the most common prescribers of dulaglutide nationally. According to IQVIA prescription data reported by the Endocrine Society, roughly 68% of GLP-1 receptor agonist prescriptions originate from non-specialist providers. This means a patient in rural Coos County has the same access pathway as someone in Manchester or Nashua, provided a telehealth or local primary care appointment is available.

What Labs Are Required Before Starting Trulicity

A prescriber will order baseline labs before initiating dulaglutide. The standard panel includes HbA1c (to confirm glycemic status and establish a treatment baseline), fasting blood glucose, a comprehensive metabolic panel covering kidney and liver function, and a lipid panel. These labs serve a dual purpose: confirming the type 2 diabetes diagnosis and ruling out contraindications.

Dulaglutide carries an FDA boxed warning regarding thyroid C-cell tumors observed in rodent studies. Clinicians should assess personal and family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) before prescribing. A baseline calcitonin level is not universally required but may be drawn if the personal history warrants it, per ADA Standards of Care 2024.

Estimated GFR is particularly important. While dulaglutide does not require dose adjustment for mild-to-moderate renal impairment (eGFR 15 to 89 mL/min/1.73 m²), the REWIND trial excluded patients with eGFR below 15 [1]. A prescriber seeing borderline renal function may opt for closer monitoring or a nephrology consult.

Most New Hampshire labs, including Quest Diagnostics and Labcorp locations in Concord, Nashua, and Manchester, can turn around these results in 24 to 48 hours. Telehealth platforms typically provide a lab requisition that can be used at any in-network draw site.

Telehealth Options for New Hampshire Residents

Telehealth is the fastest route to a Trulicity prescription for many New Hampshire patients. The state's telehealth parity law (NH RSA 415-J) requires commercial insurers to reimburse telehealth visits at the same rate as in-person visits, removing a financial barrier that exists in some other states.

A typical telehealth workflow looks like this: the patient schedules a video consultation, provides medical history and recent labs (or receives a lab order), and the clinician evaluates whether dulaglutide is appropriate. If the prescription is written, it is sent electronically to the patient's pharmacy of choice. Most platforms complete this process within 3 to 7 business days from sign-up to prescription transmission.

Patients should verify two things before selecting a telehealth provider. First, that the prescribing clinician holds a valid New Hampshire license. Second, that the platform handles prior authorization on the patient's behalf, since the PA process can delay fulfillment by 5 to 10 business days if the patient is left to manage it alone.

The American Telemedicine Association has documented that telehealth-managed diabetes care produces HbA1c reductions comparable to in-person management, with a pooled analysis of 42 studies finding a mean HbA1c reduction of 0.64% in telehealth cohorts. This suggests that ongoing Trulicity management via telehealth is clinically sound, not just a convenience measure.

Insurance Coverage and Prior Authorization in New Hampshire

Commercial insurance plans in New Hampshire generally cover Trulicity, but nearly all require prior authorization. The PA process requires the prescriber to submit documentation showing that the patient has a confirmed type 2 diabetes diagnosis (ICD-10 code E11.x), has tried or has a contraindication to metformin, and has a recent HbA1c value. Some plans also require documentation of BMI.

New Hampshire Medicaid (NH Medicaid Care Management) does not currently list Trulicity on its preferred drug list for type 2 diabetes. Patients enrolled in NH Medicaid may need to explore manufacturer savings programs or appeal for non-formulary coverage. Eli Lilly's Trulicity Savings Card can reduce out-of-pocket costs to as low as $25 per month for commercially insured patients, though this benefit does not apply to government insurance programs.

The prior authorization documentation package should include:

• A completed PA form (specific to the patient's plan)
• Lab results showing HbA1c of 7.0% or higher
• A medication history demonstrating metformin trial or documented intolerance
• The prescriber's clinical rationale for GLP-1 RA therapy

A denied PA can be appealed. New Hampshire Insurance Department regulations require insurers to process standard PA requests within 72 hours and urgent requests within 24 hours. If denied, patients have the right to an external review through the NH Insurance Department.

For uninsured patients, Trulicity's list price is approximately $950 to $1,050 per month for a single pen. Manufacturer patient assistance programs through Eli Lilly's LillyDirect may provide the drug at no cost for qualifying patients below 400% of the federal poverty level.

Pharmacy Access and 503A Compounding in New Hampshire

Trulicity is stocked at major chain pharmacies throughout New Hampshire, including CVS, Walgreens, and Rite Aid locations. Specialty pharmacies may be required by some insurance plans, particularly for initial fills. Patients in rural areas of the state (the North Country, for example) can use mail-order pharmacy services, which typically deliver within 3 to 5 business days via cold-chain shipping.

New Hampshire does license 503A compounding pharmacies. These pharmacies can compound dulaglutide for individual patients with a valid prescription, provided the compounded product meets FDA and state Board of Pharmacy standards under section 503A of the Federal Food, Drug, and Cosmetic Act. This pathway is relevant for patients who need a non-standard dose or formulation, though the vast majority of patients will use the commercially manufactured product.

A 503A pharmacy in New Hampshire must hold an active compounding license from the NH Board of Pharmacy and comply with USP 797 sterile compounding standards. Patients should confirm that any compounding pharmacy they use carries appropriate licensure and can document the potency and sterility of the compounded product.

Cold-chain integrity matters. Dulaglutide pens must be stored at 36 to 46°F (2 to 8°C) prior to first use. Once removed from refrigeration, a pen may be kept at room temperature (up to 86°F) for up to 14 days. Mail-order pharmacies shipping to New Hampshire addresses during summer months should use insulated packaging with cold packs, and patients should inspect the temperature indicator upon delivery.

Clinical Evidence Supporting Dulaglutide

The REWIND trial (Researching Cardiovascular Events with a Weekly Incretin in Diabetes) provides the strongest evidence base for dulaglutide's cardiovascular benefit. This multinational trial enrolled 9,901 patients with type 2 diabetes and followed them for a median of 5.4 years. Dulaglutide 1.5 mg weekly reduced the composite endpoint of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke by 12% compared to placebo (HR 0.88; 95% CI 0.79 to 0.99; P=0.026) 1.

Two details from REWIND are particularly relevant for New Hampshire prescribers. First, 31% of enrolled patients did not have established cardiovascular disease at baseline, making REWIND one of the few GLP-1 RA trials to show benefit in a primary prevention population. Second, the mean HbA1c reduction from baseline was 0.61% at 5 years, a durable effect that compares favorably with other agents in the class.

The AWARD trial program established dulaglutide's glycemic efficacy across multiple comparator arms. AWARD-1 (N=978) demonstrated that dulaglutide 1.5 mg reduced HbA1c by 1.51% at 26 weeks compared to 0.99% with exenatide 10 mcg twice daily. AWARD-3 (N=807) showed superiority over metformin monotherapy in treatment-naive patients, with HbA1c reductions of 0.78% for dulaglutide 1.5 mg versus 0.56% for metformin at 52 weeks 2.

The ADA Standards of Care recommend GLP-1 receptor agonists with proven cardiovascular benefit (including dulaglutide) as preferred second-line therapy after metformin in patients with established atherosclerotic cardiovascular disease or high cardiovascular risk. This recommendation carries a Level A evidence grade, the highest tier.

Transferring a Trulicity Prescription to New Hampshire

Patients relocating to New Hampshire or splitting time between states can transfer an existing Trulicity prescription. The process requires the receiving New Hampshire pharmacy to contact the originating out-of-state pharmacy and verify the prescription details. New Hampshire does not impose additional restrictions on controlled substance transfers for GLP-1 receptor agonists because dulaglutide is not a scheduled substance.

If the prescriber is not licensed in New Hampshire, the patient will need to establish care with a New Hampshire-licensed provider. A telehealth visit with documentation of prior treatment history (pharmacy records, prior authorization approval letters, recent labs) is typically sufficient to maintain continuity of therapy without a gap.

Patients should request a 90-day supply before a planned move to allow time for establishing new provider relationships and pharmacy accounts. Most commercial insurance plans allow 90-day fills at mail-order pharmacies, which also avoids the geographic constraint entirely.

Dosing and Titration Schedule

Dulaglutide is initiated at 0.75 mg subcutaneously once weekly. If additional glycemic control is needed after at least 4 weeks, the dose can be increased to 1.5 mg weekly. The FDA-approved labeling also permits escalation to 3.0 mg and 4.5 mg weekly in patients who need further HbA1c lowering, though doses above 1.5 mg were not studied in REWIND.

The injection is administered in the abdomen, thigh, or upper arm, and the site should be rotated each week. Patients can inject on any day of the week, but the same day should be chosen consistently. If a dose is missed and the next scheduled dose is more than 3 days (72 hours) away, the missed dose should be taken as soon as possible. If fewer than 3 days remain, the patient should skip the missed dose.

Common side effects include nausea (reported in 12.4% of patients at the 0.75 mg dose and 21.1% at 1.5 mg in clinical trials), diarrhea (8.9% and 12.6% respectively), and decreased appetite 3. Nausea typically diminishes after 2 to 4 weeks and can be managed by eating smaller meals and avoiding high-fat foods during the titration period.

Timeline from Consultation to First Injection

The typical timeline for a New Hampshire patient, from initial consultation to first injection, spans 5 to 14 days. The breakdown looks like this: telehealth or in-person visit (day 1), lab results returned (days 2 to 3), prescription sent to pharmacy (day 3 to 4), prior authorization processed (days 4 to 10), and pharmacy dispensing (days 10 to 14). Patients with recent qualifying labs and commercial insurance with a streamlined PA process may receive their first pen in as few as 5 days.

Delays most commonly occur at the prior authorization stage. Patients can reduce this delay by ensuring their prescriber submits PA documentation proactively (rather than waiting for a pharmacy rejection to trigger the process) and by choosing a pharmacy experienced with specialty medications.